Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 76420-905

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 76420-905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Esomeprazolemagnesiumfigure1 (Esomeprazolemagnesiumfigure1)

Chemical structure of Esomeprazole Magnesium trihydrate showing the molecular arrangement of atoms including methoxy, sulfinyl, and pyridine groups bound to magnesium ion complexed with three water molecules.*

FDA Label Image

Label (Esomeprazole 20mg)

Esomeprazole Magnesium DR Capsules, USP 20 mg packaging labels by Enovachem Pharmaceuticals, showing multiple NDCs for quantities 30, 60, 90, 100, and 1000 capsules. Labels indicate delayed-release capsules in white opaque gelatin, manufactured for Camber Pharmaceuticals, Inc., with storage and dispensing cautions. Contact address is 379 Van Ness Ave., Torrance, CA.*

FDA Label Image

Label (Esomeprazole 40mg)

Packaging labels for Esomeprazole Magnesium delayed-release capsules, USP 40 mg, from Enovachem Pharmaceuticals and relabeled by Asclemed USA, Inc. Labels show various NDC codes and quantities (ranging from 30 to 1000 capsules), with manufacturing details for Camber Pharmaceuticals, Inc. Labels include barcode, storage instructions, and drug status as prescription (RX). Capsules are described as white opaque gelatin.*

FDA Label Image

Figure-2 (Figure 2)

A line graph showing the percentage maintained over a 6-month period for Esomeprazole Magnesium Delayed-Release Capsules at 40 mg, 20 mg, 10 mg, and placebo groups. The x-axis represents months (0 to 6), and the y-axis represents percent maintained (0 to 100). Each group is represented by differently styled lines and markers with a legend identifying each dosage and placebo.*

FDA Label Image

Figure-3 (Figure 3)

This line graph depicts the percentage maintained over six months for Esomeprazole Magnesium delayed-release capsules at 10 mg, 20 mg, and 40 mg doses compared to placebo. The y-axis represents percent maintained, while the x-axis shows months. Different line styles differentiate the dosage groups and placebo, with the highest percent maintained seen in the 40 mg dose group throughout the study period.*

FDA Label Image

Figure-4 (Figure 4)

A line graph comparing the percentage of patients symptom-free over 28 days among three groups: Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo. The x-axis shows diary days from 0 to 28, and the y-axis shows percent of patients symptom-free from 0 to 100. Each group has a distinct line pattern.*

FDA Label Image

Figure-5 (Figure 5)

A line graph comparing the percent of patients symptom-free over 28 days among three groups: Esomeprazole Magnesium Delayed-Release Capsules 40 mg, 20 mg, and placebo. The x-axis represents diary days from 0 to 28, and the y-axis shows the percent of patients symptom-free ranging from 0 to 100%. Both Esomeprazole groups show increased symptom-free percentages over time compared to the placebo group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.